HomeCompareNPACF vs MRK

NPACF vs MRK: Dividend Comparison 2026

NPACF yields 5.15% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPACF wins by $4943.13M in total portfolio value
10 years
NPACF
NPACF
● Live price
5.15%
Share price
$15.75
Annual div
$0.81
5Y div CAGR
98.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4943.19M
Annual income
$4,748,205,307.75
Full NPACF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NPACF vs MRK

📍 NPACF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPACFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPACF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPACF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPACF
Annual income on $10K today (after 15% tax)
$437.47/yr
After 10yr DRIP, annual income (after tax)
$4,035,974,511.59/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NPACF beats the other by $4,035,966,183.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPACF + MRK for your $10,000?

NPACF: 50%MRK: 50%
100% MRK50/50100% NPACF
Portfolio after 10yr
$2471.62M
Annual income
$2,374,107,552.95/yr
Blended yield
96.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NPACF
No analyst data
Altman Z
1.4
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPACF buys
0
MRK buys
0
No recent congressional trades found for NPACF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPACFMRK
Forward yield5.15%2.76%
Annual dividend / share$0.81$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR98.1%32.7%
Portfolio after 10y$4943.19M$56.8K
Annual income after 10y$4,748,205,307.75$9,798.13
Total dividends collected$4929.45M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NPACF vs MRK ($10,000, DRIP)

YearNPACF PortfolioNPACF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,720$1,019.55$11,206$366.19+$514.00NPACF
2$14,752$2,212.19$12,650$502.35+$2.1KNPACF
3$20,940$5,155.44$14,407$694.19+$6.5KNPACF
4$35,955$13,548.57$16,585$967.82+$19.4KNPACF
5$81,541$43,069.29$19,342$1,363.89+$62.2KNPACF
6$268,086$180,837.48$22,913$1,947.19+$245.2KNPACF
7$1,387,603$1,100,750.50$27,662$2,823.89+$1.36MNPACF
8$12,032,987$10,548,251.93$34,159$4,173.35+$12.00MNPACF
9$182,226,986$169,351,690.09$43,337$6,308.80+$182.18MNPACF
10$4,943,188,183$4,748,205,307.75$56,776$9,798.13+$4943.13MNPACF

NPACF vs MRK: Complete Analysis 2026

NPACFStock

Quadient S.A. provides business solutions for customers through digital and physical channels in France and internationally. The company offers customer experience management, business process automation, mail-related solutions, and parcel locker solutions. It provides Quadient Inspire, a software solution that helps businesses design, manage, and send personalized, omnichannel communications in large volumes. The company also offers Quadient Impress, a multichannel outbound document management platform; YayPay, account receivable process automation solutions; and Beanworks, accounts payable solution automating error-prone manual processes. In addition, it provides lines of software and hardware for preparing and sending mails in low and high volumes. Further, the company operates a pick-up, drop-off solution that offers businesses and people who need to manage their deliveries and returns. Additionally, it distributes print finishing equipment, such as guillotines, binding machines, laminating machines, and paper folding machines; provides professional and maintenance services; shipping software solutions; and automated packaging solutions. It serves financial services, healthcare, higher education, insurance, public sectors/government, retail, service providers, shipping carriers, telecommunications, and utilities industries. The company was formerly known as Neopost S.A. and changed its name to Quadient S.A. in September 2019. Quadient S.A. was founded in 1924 and is headquartered in Bagneux, France.

Full NPACF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NPACF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPACF vs SCHDNPACF vs JEPINPACF vs ONPACF vs KONPACF vs MAINNPACF vs JNJNPACF vs ABBVNPACF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.